Answers are grounded in this paper and cite their sources.
Randomized trial shows no clear efficacy of rituximab on neurofilament levels in CIDP, suggesting further research is needed.
The analysis did not demonstrate biomarker-based evidence of rituximab efficacy in CIDP. However, observed trends suggest a possible biological effect in reducing axonal injury in a subset of patients. Further studies are needed to clarify the role of sNfL in treatment monitoring and patient stratification.
No takes yet. Share an insight, caveat, or question.
Bianchi et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: